Thyroid-associated ophthalmopathy in Juvenile Grave's disease-clinical, endocrine and therapeutic aspects

Journal of Pediatric Endocrinology and Metabolism

Volumn 19, Issue 10, 2006, Pages 1193-1206

  Krassas, Gerasimos E ^a   Gogakos, Apostolos ^a  

^a PANAGIA GENERAL HOSPITAL   (Greece)

Author keywords

Corticosteroids; Graves' pediatric ophthalmopathy; Juvenile Graves' disease; Somatostatin analogs; Thyroid ophthalmopathy

Indexed keywords

ANGIOPEPTIN; ANTITHYROID AGENT; CIGARETTE SMOKE; GAMMA INTERFERON; GLUCOCORTICOID; INTERLEUKIN 1; IODINE 131; OCTREOTIDE; PENTETREOTIDE IN 111; PLACEBO; PREDNISONE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; STEROID; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROTROPIN RECEPTOR; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

BODY WEIGHT DISORDER; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; ENDOCRINE OPHTHALMOPATHY; ENVIRONMENTAL EXPOSURE; EUTHYROIDISM; EXTRAOCULAR MUSCLE; GRAVES DISEASE; GROWTH RETARDATION; HEALTH CARE POLICY; HORMONE DETERMINATION; HUMAN; HYPERTHYROIDISM; IMMUNE DEFICIENCY; MUSCLE RESECTION; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; SCINTISCANNING; SEX RATIO; T LYMPHOCYTE ACTIVATION; THYROIDECTOMY; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 34249679825     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2006.19.10.1193     Document Type: Review

References (60)

1. Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993; 329: 1468-1475.
2. Krassas GE, Heufelder AE. Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 2001; 144: 311-318.
3. Wiersinga WM. Thyroid associated ophthalmopathy: pediatric and endocrine aspects. Pediatr Endocrinol Rev 2004; 1 (Suppl 3): 513-517.
4. Tallstedt L, Norberg R. Immunohistochemical staining of normal and Graves' extraocular muscle. Invest Ophthalmol Vis Sci 1988; 29: 175-184.
5. Perros P, Kendall-Taylor P. Pathogenesis of thyroid-associated ophthalmopathy. Trends Endocrinol Metab 1993; 4: 270-275.
6. Natt N, Bahn RS. Cytokines in the evolution of Graves' ophthalmopathy. Autoimmunity 1997; 26: 129-136.
7. Bahn RS. Cytokines in thyroid eye disease: potential for anticytokine therapy. Thyroid 1998; 8: 415-418.
8. Smith TJ, Bahn RS, Gorman CA, Cheavens M. Stimulation of glycosaminoglycan accumulation by interferon gamma in cultured human retroocular fibroblasts. J Clin Endocrinol Metab 1991; 72: 1169-1171.
9. Korducki JM, Loftus SJ, Bahn RS. Stimulation of glycosaminoglycan production in cultured human retroocular fibroblasts. Invest Ophthalmol Vis Sci 1992; 33: 2037-2042.
10. Hansson HA, Petruson B, Skottner A. Somatomedin C in pathogenesis of malignant exophthalmos of endocrine origin. Lancet 1986; i: 218-219.
11. Krassas GE, Pontikides N, Doukidis D, Heufelder G, Heufelder AE. Serum levels of tumor necrosis factor-alpha, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and soluble interleukin-1 receptor antagonist in patients with thyroid eye disease undergoing treatment with somatostatin analogues. Thyroid 2001; 11: 1115-1122.
12. Heufelder AE, Bahn RS. Modulation of Graves' orbital fibroblast proliferation by cytokines and glucocorticoid receptor agonists. Invest Ophthalmol Vis Sci 1994; 35: 120-127.
13. Heufelder AE: Pathogenesis of Graves' ophthalmopathy: recent controversies and progress. Eur J Endocrinol 1995; 132: 532-541.
14. Heufelder AE, Scriba PC. Characterization of adhesion receptors on cultured microvascular endothelial cells derived from the retroorbital connective tissue of patients with Graves' ophthalmopathy. Eur J Endocrinol 1996; 134: 51-60.
15. Metcalfe RA, Weetman AP. Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy. Clin Endocrinol (Oxf) 1994; 40: 67-72.
16. Kumar S, Coenen MJ, Scherer PE, Bahn RS. Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 2004; 89: 930-935.
17. Ludgate ME. Animal models of thyroid-associated ophthalmopathy. Thyroid 2002; 12: 205-208.
18. Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2000; 52: 267-271.
19. Rotella CM, Zonefrati R, Toccafondi R, Valente WA, Kohn LD. Ability of monoclonal antibodies to the thyrotropin receptor to increase collagen synthesis in human fibroblasts: an assay which appears to measure exophthalmogenic immunoglobulins in Graves' sera. J Clin Endocrinol Metab 1986; 62: 357-367.
20. Pritchard J, Horst N, Cruikshank W, Smith TJ. Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol 2002; 168: 942-950.
21. Mizokami T, Salvi M, Wall JR. Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphenomenon? J Endocrinol Invest 2004; 27: 221-229.
22. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 1989; 73: 639-644.
23. Pinchera A, Wiersinga W, Glinoer D, Kendall-Taylor P, Koornneef L, Marcocci C, Schleusener H, Romaldini J, Niepominiscze H, Nagataki S, Izumi M, Inoue Y, Stockigt J, Wall J, Greenspan F, Solomon D, Garrity J, Gorman CA. Classification of eye changes of Graves' disease. Thyroid 1992; 2: 235-236.
24. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA. The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota. Am J Ophthalmol 1995; 120: 511-517.
25. Uretsky SH, Kennerdell JS, Gutai JP. Graves' ophthalmopathy in childhood and adolescence. Arch Ophthalmol 1980; 98: 1963-1964.
26. Young LA. Dysthyroid ophthalmopathy in children. J Pediatr Ophthalmol Strabismus 1979; 16: 105-107.
27. Gruters A. Ocular manifestations in children and adolescents with thyrotoxicosis. Exp Clin Endocrinol Diabetes 1999; 107 (Suppl 5): S172-S174.
28. Chan W, Wong GW, Fan DS, Cheng AC, Lam DS, Ng JS. Ophthalmopathy in childhood Graves' disease. Br J Ophthalmol 2002; 86: 740-742.
29. Werner SC, Coelho B, Quimby EH. Ten year results of I-131 therapy in hyperthyroidism. Bull NY Acad Med 1957; 33: 783-806.
30. Hamilton RD, Mayberry WE, McConahey WM, Hanson KC. Ophthalmopathy of Graves' disease: a comparison between patients treated surgically and patients treated with radioiodide. Mayo Clin Proc 1967; 42: 812-818.
31. Kriss JP, Pleshakov V, Rosenblum AL, Holderness M, Sharp G, Utiger R. Studies on the pathogenesis of the ophthalmopathy of Graves' disease. J Clin Endocrinol Metab 1967; 27: 582-593.
32. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren J-G, Blomgren H, Taube A; the Thyroid Study Group. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 1992; 326: 1733-1738.
33. Prummel MF, Bakker A, Wiersinga WM, Baldeschi L, Mourits MP, Kendall-Taylor P, Perros P, Neoh C, Dickinson AJ, Lazarus JH, Lane CM, Heufelder AE, Kahaly GJ, Pitz S, Orgiazzi J, Hullo A, Pinchera A, Marcocci C, Sartini MS, Rocchi R, Nardi M, Krassas GE, Halkias A. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy Experience. Eur J Endocrinol 2003; 148: 491-495.
34. Krassas GE, Segni M, Wiersinga WM. Childhood Graves' ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol 2005; 153: 515-521.
35. Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. JAMA 1993; 269: 479-482.
36. Krassas GE, Wiersinga WM. Smoking and autoimmune thyroid disease: the plot thickens. Eur J Endocrinol 2006; 154: 777-780.
37. Rivkees SA, Sklar C, Freemark M. Clinical Review 99: The management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 1998; 83: 3767-3776.
38. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989; 321: 1349-1352.
39. Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J Clin Endocrinol Metab 2005; 90: 5321-5323.
40. Krassas GE, Boboridis K. Recent developments in the medical treatment of thyroid eye disease. Orbit 2006; 25: 117-122.
41. Pasquali D, Vassallo P, Esposito D, Bonavolonta G, Bellastella A, Sinisi AA. Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy. J Mol Endocrinol 2000; 25: 63-71.
42. Pasquali D, Notaro A, Bonavolonta G, Vassallo P, Bellastella A, Sinisi AA. Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves' disease. J Clin Endocrinol Metab 2002; 87: 5125-5129.
43. 111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity? J Clin Endocrinol Metab 1994; 79: 1845-1851.
44. Kahaly G, Diaz M, Hahn K, Beyer J, Bockisch A. Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy. J Nucl Med 1995; 36: 550-554.
45. 111In-octreotide. Thyroid 1997; 7: 21-29.
46. Kahaly G, Diaz M, Just M, Beyer J, Lieb W. Role of octreoscan and correlation with MR imaging in Graves' ophthalmopathy. Thyroid 1995; 5: 107-111.
47. Krassas GE, Kahaly GJ. The role of octreoscan in thyroid eye disease. Eur J Endocrinol 1999; 140: 373-375.
48. Imai Y, Odajima R, Inoue Y, Shishiba Y. Effect of growth factors on hyaluronan and proteoglycan synthesis by retroocular tissue fibroblasts of Graves' ophthalmopathy in culture. Acta Endocrinol (Copenh) 1992; 126: 541-552.
49. Weightman DR, Perros P, Sherif IH, Kendall-Taylor P. Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity 1993; 16: 251-257.
50. Krassas GE, Pontikides N, Kaltsas T, Dumas A, Frystyk J, Chen JW, Flyvbjerg A. Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J Clin Endocrinol Metab 2003; 88: 132-135.
51. Krassas GE. Treatment of juvenile Graves' disease and its ophthalmic complication: the 'European way'. Eur J Endocrinol 2004; 150: 407-414.
52. Krassas GE. Somatostatin analogs: a new tool for the management of Graves' ophthalmopathy. J Endocrinol Invest 2004; 27: 281-287.
53. Krassas GE. Thyroid eye disease in children and adolescents - new therapeutic approaches. J Pediatr Endocrinol Metab 2001; 14: 97-100.
54. Dickinson AJ, Vaidya B, Miller M, Coulthard A, Perros P, Baister E, Andrews CD, Hesse L, Heverhagen JT, Heufelder AE, Kendall-Taylor P. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2004; 89: 5910-5915.
55. Wemeau JL, Caron P, Beckers A, Rohmer V, Orgiazzi J, Borson-Chazot F, Nocaudie M, Perimenis P, Bisot-Locard S, Bourdeix I, Dejager S: Octreotide (long-acting release formulation) treatment in patients with Graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab 2005; 90: 841-848.
56. Chang TC, Liao SL. Slow-release lanreotide in Graves' ophthalmopathy: a double-blind randomized, placebo-controlled clinical trial. J Endocrinol Invest 2006; 29: 413-422.
57. Stan MN, Garrity JA, Bradley EA, Woog JJ, Bahn MM, Brennan MD, Bryant SC, Achenbach SJ, Bahn RS. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. J Clin Endocrinol Metab 2006 Sep 19; Epub ahead of print.
58. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptide-mimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146: 707-716.
59. Wiersinga WM, Prummel MF. Retrobulbar radiation in Graves' ophthalmopathy. J Clin Endocrinol Metab 1995; 80: 345-347.
60. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000; 21: 168-199.